Abstract
Background:
Reports of vitiligo associated with metastases and rare cases of spontaneous regression of disease have fueled enthusiasm for immunologic approaches to the treatment of advanced melanoma. More recent strategies have focused on using antigen-presenting dendritic cells as vaccines.
Observations:
We observed 3 cases of leukoderma associated with a novel adenovirus-mediated gp100/MART-1-transduced dendritic cell (MART indicates melanoma antigen recognized by T cells). All 3 patients had advanced metastatic melanoma. Despite the development of this leukodermic response, all patients experienced disease progression while under treatment.
Conclusion:
We provide the initial evidence for effective induction of a leukodermic response with a gp100/MART-1-transduced dendritic cell vaccine.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenoviridae / genetics
-
Adult
-
Aged
-
Antigens, Neoplasm
-
Biopsy, Needle
-
Cancer Vaccines / administration & dosage
-
Cancer Vaccines / adverse effects*
-
Female
-
Follow-Up Studies
-
Humans
-
Hypopigmentation / chemically induced*
-
Hypopigmentation / diagnosis
-
MART-1 Antigen
-
Male
-
Melanoma / immunology
-
Melanoma / pathology
-
Melanoma / prevention & control*
-
Melanoma / secondary
-
Membrane Glycoproteins / administration & dosage
-
Membrane Glycoproteins / adverse effects*
-
Neoplasm Proteins / administration & dosage
-
Neoplasm Proteins / adverse effects*
-
Neoplasm Staging
-
Risk Assessment
-
Skin Neoplasms / immunology
-
Skin Neoplasms / pathology
-
Skin Neoplasms / prevention & control*
-
gp100 Melanoma Antigen
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
MART-1 Antigen
-
MLANA protein, human
-
Membrane Glycoproteins
-
Neoplasm Proteins
-
PMEL protein, human
-
gp100 Melanoma Antigen